Drug Development · us
Vanda’s Social Anxiety Drug Fails Phase 3 Trial; VQW-765 Development Paused
The candidate drug, intended to ease anxiety before public speaking, failed to reproduce an early signal in a large trial. Key efficacy measures in women and the overall study population were not met. Vanda will review the full data before deciding its next steps.
For people with social anxiety disorder, speaking on stage can be an overwhelming test of stress tolerance. Drugs that can be taken as needed to ease acute anxiety have therefore become one direction in drug development. However, Vanda Pharmaceuticals announced on October 14 that its candidate drug VQW-765 failed to meet the primary and key secondary efficacy endpoints in a Phase 3 trial. Development has been paused pending analysis of the full data.
The randomized, double-blind, placebo-controlled trial enrolled 546 adults with social anxiety disorder at approximately 30 sites in the United States. After receiving a single oral dose of the drug or placebo, participants underwent the standardized Trier Social Stress Test: they first prepared a speech, then delivered an interview-style presentation to a panel of judges who provided no feedback or encouragement, inducing acute stress.
The primary efficacy endpoint focused on female participants’ subjective distress during the speech phase, assessed on a scale from 0 to 100, with higher scores indicating greater anxiety. The company reported scores of 65.6 for the drug group and 66.0 for the placebo group, a difference that was not statistically significant. The same assessment across all participants, including men and women, also failed to meet the key secondary endpoint. Neither result supported an effect superior to placebo in this test.
VQW-765 is a partial agonist of the α7 nicotinic acetylcholine receptor. In an earlier Phase 2 study, participants who received the drug reported numerically lower anxiety during the stress test, but that numerical improvement still required confirmation in subsequent trials. The Phase 3 results failed to reproduce that signal, weakening the evidence for the efficacy of this as-needed treatment strategy.
The news was also reflected in the market. Reuters reported that Vanda shares fell approximately 17% in after-hours trading following the announcement and confirmed that the company would pause the program while reviewing the full data. This decision does not yet amount to permanent discontinuation of development, but there are currently no results sufficient to support resuming the program.
The company said VQW-765’s safety and tolerability were consistent with previous studies. However, the announcement did not provide detailed adverse event data, so no conclusions can be drawn from it about the risks of long-term or repeated use. This trial examined responses to a specific stressful situation after a single dose and cannot directly answer whether everyday social functioning or long-term symptoms improve. Whether further analysis can explain the discrepancy between the earlier and later trials will influence whether there is room for continued development of the program.